Can Do Multiple Sclerosis Receives 4-Star Charity Navigator Rating For Fifth Consecutive Year

September 28th, 2022

Can Do MS has once again received a 4-star rating from Charity Navigator. This is the fifth consecutive year that Can Do MS has earned the recognition.

SKI FOR MS RAISES OVER $262K FOR FAMILIES LIVING WITH MS

April 13th, 2022

SKI for MS, a fundraising ski event benefiting families living with multiple sclerosis (MS), has raised over $262k.

New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab)

October 21st, 2021

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of Ocrevus® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of a shorter two-hour infusion in minority populations.

Announcing the Second Annual Lokai Run: A Virtual Run for Hope

September 9th, 2021

Participants to make their footsteps count by choosing a cause that is meaningful to them.

This September, Celebrate All That Is Possible With Multiple Sclerosis

August 31st, 2021

This September, Can Do Multiple Sclerosis honors founder and Olympic ski medalist Jimmie Heuga (1943-2010) with the annual, Can Do Month campaign.

Multiple Sclerosis Summit on Infections and Immunizations in the Era of COVID-19

August 12th, 2021

Join NeurologyLive®, the Consortium of Multiple Sclerosis Centers (CMSC), and Can Do MS for a 90-minute virtual summit where experts in immunology, virology, and neurology discuss infections and MS, the persistence of the SARS-CoV-2 virus, the impact of viral variants, the current vaccine landscape, and DMT guidance in a joint forum tailored for healthcare providers as well as patients and caregivers.

MS in Harmony: Helping People Living With Multiple Sclerosis Achieve Mind-Body Harmony Through Music Therapy

July 6th, 2021

MS in Harmony: Helping People Living With Multiple Sclerosis Achieve Mind-Body Harmony Through Music Therapy

New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

April 26th, 2021

New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis

March 19th, 2021

TITUSVILLE, N.J., March 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

SKI for MS Launches Virtual Vertical Challenge to Help Families Living With MS

January 22nd, 2021

SKI for MS, a fundraising ski event benefiting families living with multiple sclerosis (MS), has gone virtual for the 2021 season.

RECENT NEWS